Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
4(57%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
1
14%
Ph phase_1
5
71%

Phase Distribution

5

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(2)
Terminated(1)

Detailed Status

Recruiting3
Completed2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (83.3%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting114%
completed229%
recruiting343%
terminated114%

Recent Activity

4 active trials
Showing 5 of 7
recruitingphase_3

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

NCT06915727
recruitingphase_1

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

NCT05901545
terminatedphase_1

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

NCT05316688
recruitingphase_1

Bronchial NIR Image-guided Resection

NCT03097575
active_not_recruitingphase_1

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

NCT00264602
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06915727Phase 3

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

Recruiting
NCT05901545Phase 1

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Recruiting
NCT05316688Phase 1

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

Terminated
NCT03097575Phase 1

Bronchial NIR Image-guided Resection

Recruiting
NCT00264602Phase 1

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

Active Not Recruiting
NCT05919576

Near Infrared Technology for the Detection of Proximal Caries

Completed
NCT01808417Phase 1

NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
7